Galena Biopharma, Inc. (NASDAQ:GALE) Stock Rating Reaffirmed by Maxim Group
A number of other brokerages have also commented on GALE. ValuEngine lowered shares of Galena Biopharma from a sell rating to a strong sell rating in a report on Friday, June 2nd. Zacks Investment Research lowered shares of Galena Biopharma from a buy rating to a hold rating in a report on Tuesday, May 16th.
Galena Biopharma (NASDAQ GALE) traded down 5.7119% during trading on Wednesday, reaching $0.3384. The company had a trading volume of 792,563 shares. Galena Biopharma has a 52-week low of $0.16 and a 52-week high of $4.75. The company’s market capitalization is $12.67 million. The stock has a 50 day moving average price of $0.55 and a 200-day moving average price of $0.67.
Galena Biopharma (NASDAQ:GALE) last issued its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. During the same quarter last year, the business posted ($0.07) earnings per share. On average, equities research analysts anticipate that Galena Biopharma will post ($0.56) earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the company. Virtu KCG Holdings LLC increased its stake in Galena Biopharma by 677.4% in the second quarter. Virtu KCG Holdings LLC now owns 224,050 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 195,230 shares during the last quarter. Vanguard Group Inc. increased its stake in Galena Biopharma by 1.0% in the second quarter. Vanguard Group Inc. now owns 1,332,434 shares of the biotechnology company’s stock valued at $774,000 after buying an additional 13,302 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Galena Biopharma during the first quarter valued at $976,000. 21.99% of the stock is owned by institutional investors.
Galena Biopharma Company Profile
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
Receive News & Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.